The efficacy and safety of anti CD40 monoclonal antibody in pig-to-rhesus xenogeneic deep anterior lamellar keratoplasty by 김동현
 
 
저 시-비 리- 경 지 2.0 한민  
는 아래  조건  르는 경 에 한하여 게 
l  저 물  복제, 포, 전송, 전시, 공연  송할 수 습니다.  
다 과 같  조건  라야 합니다: 
l 하는,  저 물  나 포  경 ,  저 물에 적 된 허락조건
 명확하게 나타내어야 합니다.  
l 저 터  허가를 면 러한 조건들  적 되지 않습니다.  
저 에 른  리는  내 에 하여 향  지 않습니다. 




저 시. 하는 원저 를 시하여야 합니다. 
비 리. 하는  저 물  리 목적  할 수 없습니다. 
경 지. 하는  저 물  개 , 형 또는 가공할 수 없습니다. 
의학박사 학위논문
돼지-영장류 간 이종 심부표층각막이식
에서 항 CD40 단클론항체의 유효성 및
안전성
The efficacy and safety of anti CD40 monoclonal 
antibody in pig-to-rhesus xenogeneic deep anterior 
lamellar keratoplasty





돼지-영장류 간 이종 심부표층각막이식
에서 항 CD40 단클론항체의 유효성 및
안전성
The efficacy and safety of anti CD40 monoclonal 
antibody in pig-to-rhesus xenogeneic deep anterior 
lamellar keratoplasty





돼지-영장류 간 이종 심부표층각막이식
에서 항 CD40 단클론항체의 유효성 및
안전성
지도교수 김 미 금
이 논문을 의학박사 학위논문으로 제출함




김동현의 의학석사 학위논문을 인준함
2017 년 6 월
위 원 장     현 준 영 (인)
부위원장     김 미 금 (인)
위    원     허 장 원  (인)
위    원     이 형 근 (인)
위    원     이 원 우 (인)
ii
ABSTRACT
Purpose: Corneal xenotransplantation is an effective solution for the shortage 
of human donor corneas, and the porcine cornea may be a suitable candidate 
for the donor cornea because of its optical similarity with humans. However, 
it is necessary to administer additional immunosuppressants to overcome 
antigenic differences. We aimed to investigate the feasibility of porcine 
corneas with anti-CD40 antibody-mediated co-stimulation blockade in a 
clinically applicable pig-to-nonhuman primate corneal xenotransplantation 
model.
Methods: Five Chinese rhesus macaques underwent deep-lamellar corneal 
transplantation using clinically acceptable sized (7.5 mm diameter) porcine 
corneal grafts. The anti-CD40 antibody was intravenously administered on a
programmed schedule. Graft survival, central corneal thickness, and 
intraocular pressure were evaluated. Changes in effector and memory T cell 
subsets and anti-αGal and donor-specific antibodies were investigated in the 
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blood, and the changes in complement levels in the aqueous humor and blood 
were evaluated. Memory cell profiles in the anti-CD40 antibody-treated group 
were compared with those in from the anti-CD154 antibody-treated group or 
rejected controls presented in our previous report. The changes in anti-αGal, 
non-αGal, and donor-specific antibodies after 6 months were compared with 
baseline values.
Results: Anti-CD40 antibody-mediated co-stimulation blockade resulted in 
the successful survival of xenocorneal grafts (> 389, > 382, > 236, > 201, and
> 61 days), with 80% reaching 6 months of survival. Injection of anti-CD40 
antibody considerably reduced the infiltration of inflammatory cells into the 
grafts and significantly blocked the complement response in the aqueous
humor (p = 0.0159, Mann-Whitney U test). Systemic expansion of effector 
memory T cells was abrogated in the anti-CD40 antibody-treated primates 
compared with those in the rejected controls (p<0.05, Mann-Whitney U test).
The levels of anti-αGal, non-αGal, and donor-specific antibodies at 6 months 
iv
were not significantly increased compared with baseline levels (p > 0.05, 
Wilcoxon signed rank test).
Conclusion: An anti-CD40 antibody-mediated blockade appears to be 
effective immunosuppressive approach for porcine corneal deep anterior 
lamellar xenotransplantation in primates. In the future clinical trials of 
xenocorneal transplantation, the anti-CD40 antibody will be effective in 
immunosuppression.
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Corneal blindness is one of the major causes in permanent visual loss world-
widely, which can be only cured by corneal transplantation.1 In several Asian 
countries including Korea, severe shortages of donor corneas have persisted 
because Confucian culture make it hard to obtain corneas from cadavers.2-4
Additionally, aging of population and increase of cataract and corneal 
refractive surgery gradually reduce population pool which can present donor 
cornea in the long term. To overcome a world-wide shortage problem in donor 
cornea, the use of artificial cornea, bio-engineered regenerative cornea using 
induced pluripotent stem cells (iPS), and corneal xenotransplantation has been 
actively investigated.2-4 However, possibility of tumorigenesis and difficulty 
in purifying specific cellular population exist in bio-engineered technique 
with iPS, and artificial cornea can cause severe tissue necrosis or immune 
reaction. Presently, corneal xenotransplantaion may be most feasible 
compared to iPS technology or artificial cornea because pig cornea is 
optically and physiologically comparable with human cornea, and pig can 
easily breed without major ethical problems.
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The major hurdles of xenotransplantation coming into clinical trials are 
Galalpha1,3Galbeta1,4GlcNAc-R (αGal) epitope-mediated rejection and 
porcine endogenous retroviruses (PERVs)-mediated zoonosis.5,6 Recent 
advances in xenotransplantation by development in a-1,3-
galactosyltransferase gene knockout (GTKO) pigs and by development of 
genome-wide inactivation of PERVs using CRISPR-Cas9 takes us a step 
closer to commercially available xenografts and clinical trials along with the 
emerging evidence of the lack of transmission of PERVs in human studies.7-9
Nevertheless, using GTKO pigs as a donor, optimized immune modulatory 
regimen should be still required as a critical step in xenotransplantation to 
achieve a successful outcome.10 Recent long-term success of porcine corneal 
xenografts by anti-CD154 antibody (Ab)-mediated costimulation blockade in 
non-human primates (NHPs) created the possibility of clinical trials in corneal 
xenotransplantation.11 However, anti-CD154 antibodies appear to greatly 
increase the incidence of thromboembolic complications and are impossible to 
use in human, despite a remarkable effect on transplantation.12-15 Anti-CD40 
antibody can be an alternative target in CD40/CD154 costimulation blockage 
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pathway. CD40 is expressed on B cells, macrophages, and dendritic cells, and 
CD8 T cells, however the thromboembolic complications with anti-CD154 
therapy appear to be related with CD40-independent pathway.16 Therefore, 
immunosuppression with anti-CD40 antibody may be potent and safe in 
xenocorneal transplantation.16
Accordingly, we investigated the effect of anti-CD40 Ab-mediated
costimulation blockade on clinical efficacy using a pig-to-NHP deep lamellar-




All procedures used in this study conformed to the ARVO Statement 
Regarding the Use of Animals in Ophthalmic and Vision Research. The 
primate study protocol was approved by the Research Ethics Committee at 
Seoul National University Hospital [IACUC No. 13-0221-C1A0(1)].
Donors and recipients
Porcine corneas were obtained from genetically unmodified, pathogen-free 
SNU miniature wild type (WT) pigs that had been inbred in the 
Xenotransplantation Research Center at Seoul National University Hospital. 
Five Chinese rhesus macaques were used as recipients for deep anterior 
lamellar-thickness porcine corneal grafts (Table 1).
Orthotopic pig-to-rhesus deep anterior lamellar corneal transplantation
The donor corneoscleral buttons had been preserved in Optisol (Chiron 
Ophthalmics, Irvine, California) for 1~5 days before transplantation. Anterior 
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lamellae in donor cornea were incised 687.5- to 750-μm-thick with a 7.5-mm-
diameter Barron vacuum trephine (Katena Products Inc., Denville, NJ) and 
artificial anterior chamber (Moria, Pennsylvania, USA). Deep-lamellar central 
portions of corneas were incised from recipients’ eyes using 7.5-mm-diameter 
Hessburg-Barron vacuum trephines (Katena Products Inc., Denville, NJ) and 
the endothelial layer was separated from the full stromal layer using a big 
bubble technique as previous reported.17,18 After removal of deep anterior 
lamellar recipient stromal layer, xenografts were placed in each recipient bed 
and secured with 16~20 interrupted 10-0 nylon sutures (Ethicon, Somerville, 
NJ). At the end of the surgical procedure, a contact lens (Acuvue® Oasys™, 
Johnson & Johnson, Jacksonville, FL) was inserted, and eyelids were closed 
with 6-0 black silk for 1 day.
Postoperative local and systemic immunosuppressive regimen 
Postoperatively, all the recipients received the same medications. 
Levofloxacin 0.5% (Cravit®, Santen Pharmaceutical, Osaka, Japan) and 
prednisolone acetate 1% (Pred forte®, Allergan, Irvine, CA) were topically 
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administered once a day. Dexamethasone 1.5 mg/0.3 ml (JW Pharmaceutical, 
Seoul, Republic of Korea) was injected weekly subconjunctivally for up to 6 
months and methylprednisolone (Solu-medrol®, Pfizer, New York, NY) was 
injected intramuscularly at an initial dose of 2 mg/kg/day, tapered over 5 
weeks, and discontinued at a final dose of 0.25 mg/kg.19 Intravenous 
immunoglobulin G (IVIG) and anti-CD 40 Ab were administered during the 6 
months after transplantation. IVIG (1g/kg) was slowly administered on day 0 
and 2 weeks post-transplantation. A mouse-rhesus chimeric monoclonal anti-
CD40 (2C10R4, NIH Nonhuman Primate Reagent Resource) previously 
described,20 was administered intravenously at a dose of 50~30mg/kg/day on 
day -1, day 1, postoperative day (POD) 4, POD 7, POD 10, and POD 14, once 
weekly until week 4, every 2 weeks until week 12, and then every 4 weeks 
until week 24 (15 times in total, 50 mg/kg/day in first 8 times and 30 




Grafts were evaluated by slit-lamp biomicroscopy, particularly for graft 
clarity, edema, and neovascularization. A graft rejection score on a scale of 0 
to 12, was calculated based on the combined scores of graft clarity, edema, 
and neovascularization—each of which was scored on a scale of 0 to 4. The 
scoring system used was as follows22, 23: for clarity: 0, clear cornea; 1, slight 
haze; 2, increased haze but anterior chamber structures still clear; 3, advanced 
haze with difficult view of the anterior chamber; 4, opaque cornea without 
view of the anterior chamber; for edema: 0, no stromal or epithelial edema; 1, 
slight stromal thickness; 2, diffuse stromal edema; 3, diffuse stromal edema 
with microcystic edema of epithelium; 4, bullous keratopathy; for 
neovascularization: 0, no vascularization at graft-host junction (GHJ); 1, 
vascularization at GHJ in one quadrant only; 2, vascularization at GHJ in two 
quadrants only; 3, vascularization at GHJ in three quadrants only; 4, 
vascularization at GHJ in all four quadrants. Graft scores exceeding 6 and 
corneal clarity for 4 weeks was considered graft rejection. During the follow-
up period, loosened, exposed, or new vessel-inducing sutures were selectively 
removed. Central corneal thickness (CCT) and intraocular pressure (IOP) 
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were measured using an ultrasonic pachymeter (Quantel Medical, Clermont-
Ferrand, France) and a Tono-Pen (Medtronic Solan, Jacksonville, FL), 
respectively. The results are the mean values of 5 measurements. For 
visualization for living endothelial cells, enucleated eyeballs from the 
sacrificed recipients were evaluated using a SP-3000 specular microscope 
(Topcon Medical Laser Systems, Inc., Santa Clara, CA). The changes of 
endothelial cell density were compared between before and 6 months after 
transplantation in subjects in which data of endothelial cell density of donor 
were available before transplantation (n=3). For evaluation of corneal 
thickness and astigmatism, examinations using Orbscan IIz topography 
system (Bausch & Lomb, UT, USA) and anterior segment optical coherence 
tomography (Carl Zeiss Meditec, AG, Oberkochen, Germany) were 
performed in enucleated eyeballs.      
Immunohistochemistry of xenografts 
Corneas from sacrificed recipients were divided into two equal parts and each 
portion of the cornea was subjected to hematoxylin and eosin (H&E), 
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immunohistochemical and immunofluorescent staining as described 
previously.11 Immunohistochemical staining of the grafts was performed using 
anti-CD68 Abs (Thermo Scientific, Runcorn, United Kingdom; 1:100) and 
Diaminobenzidine (DAB)-conjugated secondary antibody (Roche, Mannheim, 
Germany) for visualization. Immunofluorescence staining of the grafts was 
performed using (1) anti-CD3 Abs (Abcam, Cambridge, USA, 1:200) and 
goat anti rabbit IgG-FITC (SouthernBiotech, Birmingham, USA, 1:500) as 
well as anti-CD8 Abs (Abcam, Cambridge, USA; 1:150) and goat anti mouse
IgG-Cy3 (Millipore, California, USA, 1:500) for CD3+CD8+ T cells; (2) anti-
CD3 Abs (Abcam, Cambridge, USA, 1:200), goat anti rabbit IgG-Cy3 
(Millipore, California, USA, 1:200) and anti-CD4-alexa fluor 488 conjugated 
Abs (Novusbio, Littleton, USA; 1:50) for CD3+CD4+ T cells; and (3) anti-
CD3 Abs (Abcam, Cambridge, USA, 1:200) and goat anti rabbit IgG-FITC 
(SouthernBiotech, Birmingham, USA, 1:500) as well as anti-CD20 Abs 
(eBioscience, San Diego, USA; 1:100) and goat anti mouse IgG-Cy3 
(Millipore, California, USA, 1:500) for CD3-CD20+ B cells. Counter nuclear 
staining was done using DAPI (4',6-diamidino-2-phenylindole). To 
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investigate the distribution of αGal epitopes, the Griffonia simplifolia I 
isolectin B4 (GSIB4; Molecular Probes, Eugene, OR) conjugated with Alexa 
fluor 488 (I-21411; Molecular Probes) was reacted with the corneal tissue as 
described previously.11 To confirm the deposition of IgG Abs in the corneal 
tissues, fluorescein isothiocyanate (FITC) polyclonal goat anti-monkey IgG 
(Fc specific) Abs (AP31438FC-N; 1:20, Acris Antibodies Inc., San Diego, 
CA) were used, per the manufacturer’s protocol. To confirm the deposition of 
complement C3c in the corneal tissues, polyclonal rabbit anti-human C3c Abs 
(A0062; 1:100, DAKO) were used as a primary Ab and Alexa Fluor 488 goat 
anti-rabbit IgG Abs (A11304; 1:500, Life technologies, Grand Island, NY) 
were used as the secondary Ab. The nuclei of cells were then counterstained 
with Hoechst33342 and the distribution of IgG Ab and complement C3c was 
investigated with Venoz AHBT3/Q fluorescent microscopy (Olympus, Tokyo, 
Japan). Histologic findings in anti-CD40 treated primates were compared with 
rejected controls (n=2, Table 1) that were given topical and systemic steroid 
after keratoplasty, using a previous study as the reference.19
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Memory T cell assay 
Postoperative changes in memory T-cell sub-populations (CD28+CD95+
central memory and CD28-CD95+ effector memory) were evaluated by flow 
cytometry analysis of whole blood and draining lymph nodes as previously 
mentioned.11 Data were acquired using a FACSCanto flow cytometer 
(Becton-Dickinson, Mountain View, CA) and data analysis was carried out 
using FlowJo software (Tree Star, Ashland, OR). The changes of memory T 
cell expansion of the blood over time in anti-CD40 Ab-treated primates (n=5) 
were compared to those in anti-CD154 Ab-treated primates (n=4) with 
porcine corneal grafts which survived successfully as previous described (as a 
reference) to confirm whether the T cell responses are effectively controlled 
in tolerable range.11,19 In addition, mean percentages and numbers of effector 
or central memory T cells in draining lymph nodes were compared between 
anti-CD40 Abs-treated primates (n=4) and rejected controls (n=2, Table 1) 
that were given topical and systemic steroid after keratoplasty, using a 
previous study as the reference.11,19 The lymph nodes of anti-CD40 treated 
primates were collected after 6 months and those of the rejected controls in 
12
which lymph nodes had been available were collected after 1months on 
sacrifice.
Anti-αGal and anti-non-αGal antibodies assay
Plasma levels of anti-αGal IgG and IgM Abs were measured by ELISA as 
described previously.24,25 In brief, mean absorbance of anti-αGal Abs was 
expressed as artificial units (AU)/mL, and was compared with that of a 
calibrator. As a calibrator, serial dilutions of a selected rhesus monkey plasma 
were designated as 2,809AU/mL of anti-αGal IgG and 5,610AU/mL of anti-
αGal IgM. Anti-αGal IgG Ab or anti-non-αGal IgG Ab binding responses 
were assessed by flow cytometry using a GTKO porcine endothelial cell lines 
(PEC69), and for supplemental purposes, WT porcine endothelial cells (MPN) 
incubated with 1/10 diluted plasma samples.24 The level of antibody binding 
was determined as the net mean fluorescence intensity (nMFI). nMFI values 
were calculated by subtracting MFI values of the porcine plasma (negative 
control) from MFI values of the sample. The plasma concentration or MFI 
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were measured every 2 weeks up to 4 months, and thereafter every 1 month 
until sacrifice. Mean MFI levels and plasma concentration of anti-αGal IgG 
and IgM Abs or anti-non-αGal IgG Ab at 6 months were compared with those 
prior to treatment (n=4).
Donor pig-specific antibodies assay
Plasma concentrations of donor pig-specific IgM/IgG Abs were determined by
the flow cross-match technique as described previously using donor 
peripheral blood mononuclear cells (PBMCs) as targeting cells.11
Concentrations of donor pig-specific Abs were semi-quantitatively expressed 
as the MFI. MFIs of donor serum were used as negative controls and net MFI 
(nMFI) values were calculated by subtracting donor MFI values from 
respective sample MFI values. The plasma concentration or MFI were 
measured every 2 weeks up to 4 months, and thereafter every 1 month until 
sacrifice. Mean MFI levels of donor-specific IgG and IgM Abs at 6 months 
were compared with those prior to treatment (n=4).
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Complement assay in aqueous humor
Concentration of C3a in the aqueous humor was evaluated by commercial 
ELISA kits (BD OptEIA™ Human C3a ELISA Kit; BD Biosciences, San 
Diego, CA) according to the manufacturer’s protocols prior to transplantation
and 1 months, 3 months and 6 months after transplantation. The changes of 
complement in anti-CD40 Abs treated primates (n=5) at 1 month were 
compared to those in controls with rejected grafts (n=4, Table 1) that were
given the topical and systemic steroid in previous study or topical and 
systemic steroid combined with tacrolimus and IVIG after keratoplasty as a 
reference.19 The changes of complement in anti-CD40 Abs treated primates at 
6 month were also compared with those prior to surgery (n=4). 
Safety monitoring
Safety monitoring in anti-CD40 Abs treated primates was performed because 
potent immunosuppression of anti-CD40 Abs may cause several systemic 
disorders. Weight, body temperature, complete blood discount (CBC), and 
blood chemistry panel (liver, renal, and electrolyte panel) were measured 
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every 2 weeks until week 12, and then every 4 weeks thereafter. Reactivation 
of rhesus cytomegalovirus (CMV) was also periodically checked until 
sacrifice. The quantification of RhCMV was determined by real-time PCR 
using forward and reverse primers, 50- ACAGAGGCCAGTGGGATGTC-30 
and 50-CCCTGATGATGGGCATAGATAAG-30 and probe 50 FAM-
CCAGGCACATTCTCTGGGAGCACAC-30 TAMRA (Bioneer Co., 
DaeJeon, Korea). Their sequences are located in the highly conserved 
RhCMV 156 region and specific to RhCMV IE2.26 Anti-RhCMV antibody 
was measured using immunofluorescence assay.
Statistical analyses
GraphPad Software (GraphPad Prism, Inc., La Jolla, CA, USA) was used for 
statistical tests. Mean values of C3a concentration in the aqueous humour 
were compared between anti-CD40 Abs-treated primates and rejected controls 
using the Mann-Whitney U test. Mean percentages or numbers of memory T 
cells in draining lymph nodes or blood samples were also compared between 
anti-CD40 Abs-treated primates and rejected controls or between anti-CD40 
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Abs-treated primates using the Mann-Whitney U test. The changes in anti-
αGal IgM and IgG Abs or donor-specific antibodies, the changes in 
complement and corneal endothelial cell density were compared between the 
pre-operative state and 6 months after surgery using the Wilcoxon signed rank 
test. Data are presented as mean ± standard error (SE) except demographics of 




All recipients had transparent xenocorneal grafts longer than 6 months after 
the transplantation except one that died due to anesthetic accident at 2 months 
(A clear graft was evident until death). In addition, two recipients (anti-CD40 
1 and anti-CD40 2) showed successful survival longer than a year without any 
signs of rejection (Figure 1). No corneal neovascularization was observed in 
all primates. 
The MST of the anti-CD40 Ab group ((n=5); >389, >382, >236, >201, and 
>61 days; Table 1) could not to be defined because all xenocorneal grafts of 
five recipients had survived throughout the whole study. The international 
guideline for a clinical trial of xenocorneal transplantation demands at least 6 
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months-survival of 5 in a consecutive 8 NHPs to prove an efficacy as a pre-
clinical data.24 For the welfare and animal-rights of NHPs, we tried to use 
minimal quantity of NHPs as possible as we could. Unfortunately, a primate 
had been dead during the anesthetic recovery at 2 months because the neck 
was accidentally flexed. However, we did not use additional NHPs, because in 
5 consecutive NHPs, we did not experience any rejection at all. Although the 
graft had been still survived after 6 months in remaining NHPs, we had to 
sacrifice them due to limitation of the funding. Rejection scores at sacrifice 
were 0.20±0.44 and 8.25±0.96 in the anti-CD40 antibodies and control group 
respectively. (p=0.010, Mann-Whitney U test)
The CCT was well maintained under 600μm throughout the follow-up period 
and IOPs were not increased (Figure 1C), and the density and shape of 
endothelial cells were well maintained in all recipients without significant 
reduction (p>0.05, Wilcoxon signed rank test, Figures 2). Anterior segment 
optical coherence tomographic images of the enucleated eyes showed a well-
adapted donor-recipient junction and topography showed tolerable range of 
the refractive diopter and astigmatism (Figure 2). Table 2 showed summarized 
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results of clinical examinations in enucleated eyeballs of anti-CD40 
antibodies treated primates at sacrifice. 
Neither ocular nor systemic adverse events including side effects of anti-
CD40 Ab or cytomegalovirus (CMV) infection due to long-term 
immunosuppressive therapy were observed in any recipients (Figure 3 and 4). 
Cellular infiltration into the grafted porcine cornea
In H&E stains, all recipients with anti-CD40 Abs treatment showed clear 
grafts with a few inflammatory cells confined in the donor-recipient junction 
(Figure 5A), while rejected control showed severe edema accompanying by 
abundant inflammatory cellular infiltration (Figure 5B). In 
immunohistochemical and immunofluorescent staining, CD3+CD4+ T cells, 
CD3+CD8+ T cells, CD3-CD20+ B cells and CD68+ macrophages were 
scarcely found in the surviving grafts (Figure 5A and Figure 6A; upper panel), 
while infiltration of those cells was abundantly observed in grafts of the 
rejected control, especially in graft-host junction (Figures 5B and 6B; lower 
panel).  
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Plasma donor pig-specific antibody assay and IgG deposition in porcine 
corneal grafts
The level of anti-donor specific IgM and IgG Ab were not changed 
throughout the follow-up period (Figures 7A, B and E) and differences were 
not statistically significant between the baseline and 6 month post-operative 
time point (p>0.05, Wilcoxon signed rank test). Transient peak of IgG Abs in 
early post-operative period may be caused by non-specific bindings of 
previously existing antibodies in IVIG (Figure 8A). Immunofluorescent 
staining showed IgG deposits were barely observed in the graft with anti-
CD40 Ab-treatment (Figure 7C), while deposits were densely found in the 
graft in the rejected control (Figure 7D).
Plasma anti-Gal antibody assay and αGal expression in porcine corneal 
grafts
The level of anti-αGal IgM Ab was not increased throughout the study period 
(Figure 9A, E). The level of anti-αGal IgG Ab showed subtle increase only in 
early postoperative period due to initial treatment of IVIG, and this peak had 
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no correlation with donor-specific responses (Figure 8). Thereafter, there was 
no increase of the level of anti αGal IgG Ab through the follow-up, based on 
baseline verses 6 month values (Figure 9B and E; p>0.05, Wilcoxon signed 
rank test). There were no significant changes in MFI values in the plasma 
samples against wild type porcine endothelial cells (PEC; Figure 9C, F; 
p>0.05, Wilcoxon signed rank test) or against GTKO PEC (Figure 9D) at 6 
months compared to baseline (Figure 9F; p>0.05, Wilcoxon signed rank test), 
suggesting no significant induction of anti-αGal or anti-non-αGal antibodies 
in the recipients. In immunofluorescent staining, anti-CD40 Ab-treated 
primates showed few αGal-expressing cells in the graft (Figure 9G), while the 
rejected control showed dense αGal-expressing cells (Figure 9H).
Aqueous complement C3a assay and complement C3c deposition in porcine 
corneal grafts
There was no clinically relevant increase in C3a concentration in aqueous 
humor at 6 months compared with baseline level (Figure 10A, E; p>0.05, 
Wilcoxon signed rank test). At 4 weeks after transplantation, the mean 
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aqueous C3a concentration was significantly lower in anti-CD40 Abs treated 
primates than that in rejected controls (p=0.0159, Mann-Whitney U test; 
Figure 10B). The grafts of the anti-CD40 Ab-treated primates did not show a 
deposition of C3c in the graft (Figure 10C), while graft of the rejected control 
showed pronounced deposition of C3c in the graft (Figure 10D).
Memory T cell changes in whole blood and draining lymph nodes 
The level of interferon-gamma (IFNγ) secreting CD4+ and CD8+ T cells, 
effector memory (CD28-CD95+) and central memory (CD28+CD95+) T cells 
were not higher than those in preoperative states throughout the follow-up 
(Figure 11A-F). When we compared the IFNγ+ T cells or memory and 
effector CD4+ and CD8+ T cells between the baseline and 6 months, there 
was no statistical significant increase over time in anti-CD40 treated primates 
(Figure 11G-L; p>0.05, Wilcoxon signed rank test). When we compared 
concentrations of those memory T cells at baseline, 1 month, and 6 months 
between anti-CD40 treated and anti-CD154 treated primates which showed 
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effective suppression of the clinical rejection, the concentration of CD8+ 
central memory T cells was significantly lower in anti-CD40 treated primates 
at 1 month (Figure 11L; p=0.0317, Mann-Whitney U test). The other memory 
T cell concentrations tend to be lower without statistical significance, (Figure 
11G-K; p>0.05, Mann-Whitney U test). In the draining lymph nodes, mean 
percentage of central memory (CD28+CD95+) CD4+ T cells was lower in 
anti-CD40 Ab-treated primates than in rejected controls with a marginal 
significance (p=0.082, Mann-Whitney U test; Figure 12C). The number of 
effector memory (CD28-CD95+) CD4+ and CD8+ T cells were lower in anti-
CD40 Ab-treated primates than in rejected controls (p=0.055, p=0.032, Mann-
Whitney U test; Figure 12E). The changes of IFNγ+ CD4+ and IFNγ+ CD8+ 




Table 1. Demographics of donors and recipients and graft survival with anti-CD40 Ab-primates. Demographics of anti-CD40 Ab-
primates are presented. Rejected controls given topical and systemic steroid or steroid with tacrolimus, are included as a reference for use in 
comparison of memory T cell, antibody or complement responses. 
























Anti-CD40 2 74 7.12 A 28 A >382 0
Anti-CD40 3 56 5.02 AB 30 A >236 0
Anti-CD40 4 57 5.60 B 28 A >201 1
Anti-CD40 5 57 4.80 B 28 A >61 0











Control 2* 54 4.90 AB 35 A 29 9
Control 3* 137 4.94 B 31 A 21
9













SD: standard deviation, MST: mean survival time 
* were adopted from previous study.11
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Sim K max 
(D)
Sim K min 
(D)
ACD (mm) CCT (㎛)
Anti-CD40 1 3012 23 60 57.4 52.0 3.46 642
Anti-CD40 2 3472 35 65 56.6 50.5 2.89 442
Anti-CD40 3 2257 44 52 56.6 52.0 3.80 401
Anti-CD40 4 3175 38 53 58.9 51.9 2.92 630
Anti-CD40 5 3509 26 69 50.2 47.0 2.88 383
Mean ± SD 3085±507 33.2±8.6 59.8±7.4 55.9±3.3 50.7±2.2 3.19±0.42 499±126
28
ECD: corneal endothelial cell density; CV: coefficient of varition; HEX: hexagonality; Sim K max: maximum simulated keratometric value; 
Sim K min: minimum simulated keratometric value; ACD: anterior chamber depth; CCT: central corneal thickness; SD: standard deviation
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Figure 1. Representative photographs of grafted eyes showing clinical 
courses, and changes of central corneal thickness and intraocular 
pressure in deep anterior lamellar porcine keratoplasty in nonhuman 
primates.
(A) All grafts in the anti-CD40 Abs treated primates survived at least 6 
months except one (Anti-CD40 5) which accidently died due to anesthetic 
event at POD 61. The primate also showed clear graft until death. Two of the 
grafted primates showed more than 1year survival. (B) Representative photos 
of the control showing rejection within 4 weeks.  (C) Central corneal 
thickness was well maintained under 600μm and increase of intraocular 
pressure was not observed during the follow-up in the anti-CD40 Abs treated 
primates.
30
CCT: central corneal thickness; IOP: intraocular pressure
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Figure 2. Representative of photographs of endothelial cell density (ECD) 
and refractive power in grafted eyes of anti-CD40 Abs treated primates at 
POD 201 and average data of ECDs in the surviving grafts.
(A) Endothelial cell density (ECD; CD) was well maintained showing 
3401/mm2, accompanying by normal range of coefficient of varition (CV; 26) 
and hexagonality (HEX; 72). (B) Average changes of ECD in the anti-CD40 
Abs treated primates after sacrifice with at least 6 months-survival were not 
significantly different compared to basal levels (mean ± standard error; 
p>0.05, Wilcoxon signed rank test). The primates in which both pre- and post-
operative ECD had been available were only included (n=3). (C) Anterior 
segment optical coherent tomography demonstrated well approximated wound 
and normal depth of anterior chamber. (2.92mm) (D) Topography showed 




Figure 3. Monitoring of rhesus cytomegalovirus in peripheral blood of 
the anti-CD40 Abs treated primates after corneal xenotransplantation. 
The copy numbers of Rhesus CMV (RhCMV, black line) DNA in plasma 
were determined by quantitative real-time PCR, and the antibody was titrated 
by immunofluorescence assay. Incidental increase of RhCMV copy number in 
early postoperative period was observed in anti-CD 40 treated primate 1 (anti-
CD40 1, A), followed by subsequent increase of anti-RhCMV antibody 
responses, resulting in decrease of the copy number during the follow-up. 
Clinical signs of viremia were never observed. In all the other primates (B-D), 
anti-RhCMV antibody responses (gray dot line) consistently increased upon 
increase of the copy number of RhCMV, resulting in no clinically relevant 
increase of the copy number. It suggests that an intact humoral immune 
response to CMV reactivation. 
CMV: cytomegalovirus; PCR: polymerase chain reaction.
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Figure 4. Safety monitoring in the anti-CD40 Abs treated primates.
No clinically significant changes were observed in weight, body temperature, 
CBC, renal, and liver panel.
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Figure 5. Representative findings in haematoxylin & eosin (H&E) and 
immunohistochemical staining (IHC) of porcine corneal grafts in the 
anti-CD40 Ab-treated primate and rejected control. 
(A) Staining of a surviving graft in the anti-CD40 Abs treated primates 
showed less inflammatory cell infiltration without any graft edema (Top; 
H&E, bottom; IHC using anti-CD68 Ab; arrowheads indicate donor-recipient 
junction; X40 and X200). (B) Staining of a graft in the rejected control
without anti-CD40 Ab treatment showed severe edema and inflammatory cell 
infiltration around the donor-recipient junction (Top; H&E, bottom; IHC 
using anti-CD68 Ab; arrowheads indicate the donor-recipient junction; 
magnification X40 and X200).
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Figure 6. Immunofluorescent staining for inflammatory cells infiltrating 
into the porcine corneal graft in the anti-CD40 Ab-treated primate and 
rejected control. 
A surviving graft in an anti-CD40 Ab-treated primate (A; upper panel, anti-
CD40 Ab-treated primate, magnification x200) showed few cells, while a
rejected graft (B; lower panel, rejected control; magnification x200) showed 
significant infiltration of CD3+CD4+ (CD3;red/ CD4;green double staining) 
and CD3+CD8+ (CD3; green/ CD8; red double staining) T cells as well as 
CD3-CD20+ (CD3; green /CD20; red) B cells (white arrows).
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Figure 7. Changes in plasma donor pig-specific antibodies and IgG 
deposition in porcine corneal grafts with anti-CD40 Ab-treated primates.
Few changes were observed in donor pig-specific IgM (A) and IgG (B) 
antibodies in anti-CD40 Ab-treated primates during the follow-up. Initial peak 
of anti-IgG in early postoperative days was probably caused by intravenous 
immunoglobulin treatment. Anti-CD40 Ab-treated primate showed little IgG 
deposition in the stroma (C), while A rejected control showed dense IgG 
deposition mainly in the stroma and epithelium (D) (X100). Rejected graft 
showed relatively thin epithelial layers. Dash lines and white arrows indicate 
epidermal-dermal junction. (E) Compared with basal levels, the MFI level of 
donor pig-specific IgM and IgG antibodies was not significantly high at 6 
months (p>0.05, Wilcoxon signed rank test; n=4). “Pre-op” indicates pre-
operative baseline data, and “6 mo” indicates data at 6 months post-transplant. 
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Figure 8. The conpounding effects of IVIG administration in vivo or in 
vitro on donor pig-specific and anti-αGal antibody assays. 
(A) The in vivo IgG binding responses to 3rd party PBMCs were assessed over 
time by flow cytometry using plasma of anti-CD40 Ab-treated primates (n=5) 
given IVIG infusion on day 0 and 2 weeks post-transplantation. Non-specific 
IgG binding against 3rd party PBMCs was observed during the early post-
operative period, possibly due to infusion of IVIG that may already contain 
IgG Abs against porcine PBMCs. Data are presented as mean ±standard errors 
from 5 subjects. (B) The in vitro IgG binding responses against porcine 
PBMCs were assessed by flow cytometry using plasma of a naïve primate 
when mixed with IVIG agents from different lot numbers (#1, #2). Non-
specific IgG binding against porcine PBMCs was also observed in a dose-
dependent manner after addition of IVIG into the plasma sample. (C) The 
levels of anti-αGal IgG Abs were measured by ELISA in IVIG agents from 
different lot numbers (#1, #2) and in plasma of a naïve primate mixed with 
these IVIG lots. A detectable amount of basal anti-αGal IgG was found to 
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exist in the IVIG formulations.The addition of IVIG into the naïve monkey 
plasma elevated the level of anti-αGal IgG in a dose-dependent manner. 
(PBMCs=peripheral blood mononuclear cells, MP = monkey plasma and HSA 
= human serum albumin, w/=with)
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Figure 9. Changes in plasma anti-αGal antibodies or anti-non αGal 
antibodies and αGal expression in porcine corneal grafts with anti-CD40 
Ab-treated primates. 
No significant changes were observed in IgM (A) and IgG (B) anti-αGal 
antibodies during the follow-up period (E; baseline vs 6 months, p>0.05, 
Wilcoxon signed rank test; n=4). “Pre-op” indicates pre-operative baseline 
data, and “6 mo” indicates data at 6 months post-transplant. There were no 
significant changes in the MFI values of plasma samples against wild-type 
porcine endothelial cells (PEC; C) or against GTKO PEC (D) during the 
follow-up period compared to the pre-transplantation level (F; baseline vs 6 
months, p>0.05, Wilcoxon signed rank test), suggesting no significant 
induction of anti-αGal or anti-non-αGal antibodies in the recipients. Anti-
CD40 Abs treated primate showed few αGal expressions in the stroma (G), 
while the rejected control showed dense αGal expression (H) (X100). Dash 
lines and white arrows indicate epidermal-dermal junction.
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Figure 10. Changes in concentration of aqueous humor C3a and C3c 
deposition in porcine corneal grafts in the anti-CD40 Ab-treated primate 
and rejected control.
(A, E) C3a concentration was not increased in the aqueous humor at 6 months 
compared to baseline levels (p>0.05, Wilcoxon signed rank test). (B) At 4 
weeks post-transplantation, C3a concentration in anti-CD40 Ab-treated 
primates (n=5) was significantly lower compared with that in rejected controls 
(n=4; *p=0.0159, Mann-Whitney U test). C3c deposits were barely observed 
in the graft with anti-CD40 Ab-treated primate (C), while extensive C3c 
depositions were observed in the graft of the rejected control (D; X200).
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Figure 11. Memory T cell changes in blood of anti-CD40 and anti-CD154 
Ab-treated primates after transplantation.
(A-F) The changes of IFNγ+CD4+ or IFNγ+CD8+ T cells, effector (CD28-
CD95+) memory CD4+ and CD8+ T cells, or central (CD28+CD95+) 
memory CD4+ and CD8+ T cells (black line) were not higher than those of 
preoperative states throughout the follow-up (baseline vs 6 months; p>0.05, 
Wilcoxon signed rank test; n=4) (G-K) The level of IFNγ+CD4+ or 
IFNγ+CD8+ T cells, effector/central memory CD4+ and effector memory 
CD8+ T cells were not different between anti-CD40 treated and anti-CD154 
treated primates at baseline, at 1 month, and at 6 months after transplantation 
(p>0.05, Mann-Whitney U test). (L) The level of CD8+ central memory T 
cells was significantly lower in anti-CD40 treated primates at 1 month after 
transplantation (p=0.0317, Mann-Whitney U test). CM indicates central 
memory and EM indicates effector memory.  
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Figure 12. Comparative analysis of memory T cell changes in draining 
lymph nodes between anti-CD40 Ab-treated primates and rejected 
controls.
The mean percentage of central memory (CD28+CD95+) CD4+ T cells was 
lower in anti-CD40 Ab-treated primates (n=4) than in rejected controls (n=2) 
with a marginal significance (*p=0.082, Mann-Whitney U test; C). The 
number of effector memory (CD28-CD95+) CD4+ and CD8+ T cells were 
significantly lower in anti-CD40 Ab-treated primates than in rejected controls 
(zp=0.055, zzp=0.032, Mann-Whitney U test; E). The changes of IFNγ+ CD4+
T cells were not significant. All data were analyzed after sacrifice (Anti-CD40 




Our data indicate that anti-CD40 monoclonal antibody (2C10R4) mediated-
costimulation blockade effectively suppresses xenograft-related immune 
reaction and promotes long-term survival of deep-lamellar porcine corneal 
grafts in rhesus monkeys. Blockade of CD40/CD154 costimulatory pathway 
has emerged as a promising therapeutic modality in allotransplantation, 
xenotransplantation as well as autoimmune disease models.15, 27-29 Although 
the treatment with anti-CD154 Ab has proven effective in 
xenotransplantation,30,31 anti-CD154 Ab has yielded to antagonistic anti-CD40 
Ab in the field of transplantation because of the thrombotic complications.12
Despite a prior demonstration of the comparable xenograft survival outcome 
following the use of anti-CD154 Ab and anti-CD40 Ab,29 efficacy of anti-
CD40 Ab-mediated blockage in various xenotransplantation model has not 
been clearly established. Compared with the survivals of cellular lamellar 
keratoplasty using steroids in the other reports (21days-398days),10 the 
survival of the cellular lamellar graft with anti-CD40 ab treatment seems to be 
pretty effective on corneal xenotransplantation. Most of the study achieved 0 
52
to 60% of the 6 months-survival, while our study achieved 80% of the 6 
months-survival.  
The expression of CD40 or CD154 (CD40L) varies depending on the 
cells.14,15,32 CD40 is constitutively expressed on B cells, macrophages, 
dendritic cells (DCs), monocytes, follicular dendritic cells, eosinophils and 
platelets, as well as on non-hematopoietic cells such as myofibroblasts, 
fibroblasts, epithelial, and endothelial cells. In addition, CD40 is transiently
expressed on activated CD8+ T cells. Meanwhile, CD154 inducibly expresses 
mainly on activated CD4+ T cells, activated B cells, activated CD8+ and γδ T-
cells, and platelets. Under inflammatory conditions, CD154 is also transiently 
induced on monocytes, natural killer cells, mast cells, and basophils and 
endothelial cells following activation as well as non-hematopoietic cells 
including epithelial and vascular endothelial cells, and smooth muscle cells. 
Therefore, anti-CD40 Ab-mediated blockage appears to have no direct effect 
on the activated CD4+ T cells unlike the anti-CD154 Ab-mediated blockage, 
presumably resulting in different efficacy on xeno-transplantation model.  
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From our data, anti-CD40 Ab treatment combined with IVIG showed 
effective down-regulation of donor-specific Ab responses, anti-αGal, as well 
as anti-non αGal Ab responses, complement changes and the responses of 
effector memory T cells, resulting in excellent survival of xenografts. We 
found initial peak of IgG responses which did not correlate with clinical 
progress. When we measured in vivo IgG reactivity against non-donor third 
party PBMCs using plasma from the primates given anti-CD40 Abs and IVIG 
(n=5), a similar spike was observed in early post-operative period (Figure 8A).
The increased Ig G binding against porcine PBMCs was also observed when 
mixed with plasma of a naïve primate in vitro after addition of IV IG (Figure 
8B). Plasma levels of anti-αGal IgG Abs in a naïve primate or a human were 
also increased in a dose-dependent manner after in vitro application of IVIGs 
(Figure 8C). In addition, a certain amount of anti-αGal IgG exists in IVIG 
agents. Taken together, these findings suggest that initial high peak of donor-
specific Ig G or anti-αGal level is presumably caused by administration of 
IVIG.
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The level of IFNγ+CD4+/ IFNγ+CD8+ T cells, effector memory and central 
memory T cells in the PBMCs were not higher than those between baseline 
and 6 months. It can be assumed that down-regulated dendritic cell activation 
by blockage of anti-CD40 Abs may contribute to reduced activation of CD4+
T cells. Considering that deep anterior lamellar keratoplasty without 
endothelial transplantation shows lower antigenicity than the full thickness 
keratoplasty, direct comparison of the efficacy between the anti-CD154 Ab 
and the anti-CD40 Ab is not possible in different keratoplasty settings. We 
compared the changes of T cells between the groups in order to use the data of 
anti-CD154 treated group as a reference level (negative control) to clarify the 
range that is tolerable for the T cell changes in successful survival. Compared 
to previous study with anti-CD154 Ab-treated primates, in which graft 
survival was excellent,11 no significant changes in effector or central memory 
T cells were found between anti-CD40 and anti-CD154 Ab treatment, except 
for changes in CD8+ central memory T cells, which were lower in anti-CD40 
abs-treated primates. This indicates that all of the changes in effector and
memory T cells in PBMCs appear to be within clinically tolerable ranges, 
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which corresponds well with other clinical data. In addition, the fact that the 
numbers of effector memory CD4+ and CD8+ T cells were significantly lower 
in the lymph nodes of anti-CD40 Ab-treated primates than in rejected controls 
suggests the effective control of the effector memory T cell population by 
anti-CD40 Abs.  We used mouse-rhesus chimeric form of 2C10R4 (IgG4 
isotype) as antagonistic anti-CD40 Abs. 
This anti-CD40 Ab-mediated inhibition works well in vitro and as 
corroborated by our in vivo models.33 In our study, high dosage of anti-CD40 
(50mg/kg) was initially administered for 8 times, and subsequently it was 
switched to low dosage administration (30mg/kg) for 7 times during 6 months, 
which worked efficiently. Although, human and rhesus CD40 share 95% 
homology of amino acid molecules, an in vitro study revealed lower 
inhibitory action of anti-CD40 Ab (clone of 2C10R4) against proliferation of 
human PBMCs compared with that against the proliferation of rhesus 
PBMCs.33 Therefore, adjustment of the administration may be required in 
human clinical trials in dosages and frequencies to use anti-CD40 Abs from 
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the IgG4 isotype clone, or for human usage, different isotype IgG should be 
selected to generate anti-CD40 Abs. 
One of the advantages of anti-CD40 from 2C10 appears to induce minimal 
depletion of B cells, although it effectively inhibited donor-specific and anti-α 
Gal responses. This property would be important to defense against viral 
infection under immune suppression after transplantation. In fact, our data 
(Supplementary Figure S2) revealed no clinically relevant activation of 
cytomegalovirus (CMV) infection. The antibody titers were subsequently 
increased which corresponded with the increase of the viral titer, resulting in 
no clinical activation of CMV. In addition, there were no considerable weight 
loss, fever, alanine aminotransferase changes, and blood urea 
nitrogen/creatinine changes in the anti-CD40 treatment (Supplementary 
Figure S3). All recipients showed weight loss during early postoperative 
period (average 10.2% loss from the initial weight for 2 weeks; 12.7%, 15.4%, 
6.4%, 9.9, and 6.5%), however, they recovered the weight back to normal 
after 2 weeks of transplantation.
57
Notably, we found no expression of αGal in surviving graft; by contrast, 
abundant expression of αGal was found in rejected grafts which corresponds 
with our previous studies.11 Although we do not know the exact reason why 
rejected grafts or grafts in the early post-operative period express αGal 
abundantly, it can be presumed that damaged or necrotic cells may expose 
more αGal on the cell surface due to conformational changes that are induced 
by attack from donor-specific immune cells or surgically induced 
inflammation. We presume that the reason why surviving grafts do not show 
any expression of αGals is because donor keratocytes may be slowly replaced 
in the anterior stromal grafts that have survived at least 6 months by recipient 
keratocytes from peripheral host tissues.
In conclusion, anti-CD40 Ab-mediated costimulatory blockage works well in 
deep anterior lamellar keratoplasty in NHPs. The data are a necessary and 
promising prelude to clinical trials in xenocorneal transplantation. Currently, 
we are investigating the efficacy of anti-CD40-mediated blockage in full 
thickness xenocorneal transplantation using SNU miniature WT pigs in NHPs 
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based on this study. We think the porcine cornea might be a promising
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초   록
목적: 이종각막이식은 인간 공여각막의 부족 문제를 해결할 수 있는
효과적인 방안이며, 돼지 각막은 광학적 생리학적 성질이 인간
각막과 유사하여 이종각막이식의 적절한 공여조직이라 할 수 있다. 
그러나 이종각막이식에서는 이종간 항원의 차이를 극복하기 위해
강력한 면역억제제의 사용이 필요하다. 본 연구에서는
이종각막이식의 임상적용을 큰 목표로 돼지-영장류간
심부표층각막이식 모델에서 항 CD40 항체를 통한 공자극 차단
면역억제법의 효과를 알아보고자 하였다.
방법: 다섯 마리의 영장류(Chinese rhesus macaques)에서 7.5mm 
직경의 돼지 각막을 이용하여 심부표층각막이식을 시행하였다. 
면역억제를 위해 항 CD40 항체를 정해진 계획에 맞추어 정맥내로
투여하였다. 각막편 생존여부, 중심 각막 두께, 안압을 정기적으로
측정하였고, 영장류의 혈액 내 작동 및 기억 T 세포, 항 αGal 항체, 
공여자 특이 항체, 방수 내 보체의 변화 등을 조사하였다. 항 CD40 
항체 치료군에서의 기억 T 세포 특성을 이전 연구에서의 항
CD154 항체 치료군 또는 거부반응이 생겼던 대조군에서 기억 T 
세포 특성과 비교하였다. 또한 anti CD40 항체 치료군에서 이식
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전과 이식 6 개월 후 시점에서의 항 αGal, 항 non-αGal, 공여자
특이 항체, T 세포 분포를 비교하였다.
결과: 항 CD40항체를 이용한 공자극 차단은 이종각막편의 생존을
효과적으로 유지시켰으며(389, 382, 236, 201, 61일 이상), 
80%에서 6개월 이상의 각막편 생존을 보여주었다. 항 CD40항체
투여군에서 이식 거부반응 대조군에 비해 유의하게 각막편의
염증세포의 침윤이 줄었고, 방수내 C3a 농도가 감소되었다. 
(p=0.0159, Mann-Whitney U test). 작동 기억 T 세포의 증가는
이식 거부반응 대조군에 비해 항 CD40 항체 치료군에서
효과적으로 억제되었다. (p<0.05, Mann-Whitney U test) 항
CD40항체 투여군에서 항 αGal, 항 non-αGal, 공여자 특이
항체는 이식 6개월후에도 이식 전 상태에 비해 유의하게 증가하지
않았다. (p>0.05, Wilcoxon signed rank test).
결론: 항 CD40 항체를 이용한 공자극 차단은 돼지-영장류 간 이종
심부표층각막이식에서 효과적인 면역억제법이 될 수 있다. 향후
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이종각막이식의 임상 적용시, 항 CD40 항체를 유용한
면역억제제로 사용해 볼 수 있겠다.
주요어: 항 CD40 항체, 심부표층각막이식, 영장류, 이종이식
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